ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-resorptives"

  • Abstract Number: 1221 • 2017 ACR/ARHP Annual Meeting

    Differences in BONE Metabolism between Intermittent and Continuous Treatment with LHRH Agonists in Prostate Cancer Patients

    Karla Arevalo Ruales1, Jose Ivorra Cortes1, Cesar David Vera Donoso2, Elena Grau Garcia1, Cristina Alcañiz Escandell1, Ines Canovas Olmos1, Inmaculada Chalmeta Verdejo1, Carlos Feced Olmos1, Jorge Juan Fragio Gil1, Roxana Gonzalez Mazario1, Luis Gonzalez Puig1, Eztizen Labrador Sanchez1, Isabel Martinez Cordellat1, Carmen Najera Herranz1, Rosa Negueroles Albuixech1, Jose Eloy Oller Rodriguez1, Francisco Miguel Ortiz-Sanjuán1, Elvira Vicens Bernabeu1, David Hervás Marín3, Marta De la Rubia Navarro1 and Jose Andres Roman Ivorra1, 1Rheumatology Department. Hospital Universitario y Politecnico La Fe, Valencia, Spain, 2Urology Department. Hospital Universitario y Politecnico La Fe, Valencia, Spain, 3Biostatistics Unit. IIS La Fe, Valencia, Spain

    Background/Purpose: Prostate cancer is the most common male malignancy. It is hormone dependent and androgenic inhibition with LHRH agonists is one of the mainstays of…
  • Abstract Number: 1224 • 2017 ACR/ARHP Annual Meeting

    BONE Metabolism in LIVER Transplant Patients Two-Year Study. Influence of Medical Intervention PRIOR to Surgery and Antiresorptive Treatment

    Eztizen Labrador Sanchez1, Elena Grau Garcia1, Karla Arevalo Ruales1, Jorge Juan Fragio Gil1, Roxana Gonzalez Mazario1, Cristina Alcañiz Escandell1, Ines Canovas Olmos1, Inmaculada Chalmeta Verdejo1, Carlos Feced Olmos1, Luis Gonzalez Puig1, Jose Ivorra Cortes1, Isabel Martinez Cordellat1, Carmen Najera Herranz1, Rosa Negueroles Albuixech1, Jose Eloy Oller Rodriguez1, Francisco Miguel Ortiz-Sanjuán1, Elvira Vicens Bernabeu1, Victoria Fornes Ferrer2, David Hervás Marín2, Marta De la Rubia Navarro1, Angel Moya Herraiz3 and Jose Andres Roman Ivorra1, 1Rheumatology Department. Hospital Universitario y Politecnico La Fe, Valencia, Spain, 2Biostatistics Unit. IIS La Fe, Valencia, Spain, 3Hepatology Department. Hospital Universitario y politecnico La Fe, Valencia, Spain

    Background/Purpose: Osteoporosis is a frequent complication in patients with chronic liver diseases, mainly in advanced stages or with evidence of cholestasis. During the first few…
  • Abstract Number: 1343 • 2017 ACR/ARHP Annual Meeting

    Gingival Bleeding and Periodontitis in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study

    Takefumi Furuya1, Eisuke Inoue2, Shigeru Maeda3, Eiichi Tanaka1, Katsunori Ikari1, Ayako Nakajima1, Atsuo Taniguchi1 and Hisashi Yamanaka1, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, 3Department of Dental Anesthesiology, Okayama University Hospital, Okayama, Japan

    Background/Purpose: Oral health is an important issue for patients with rheumatoid arthritis (RA) because periodontitis is a potential risk factor for RA and RA patients…
  • Abstract Number: 2986 • 2016 ACR/ARHP Annual Meeting

    Trends and Determinants of Osteoporosis Prevention and Management in Patients with Rheumatoid Arthritis Compared to Osteoarthritis

    Gulsen Ozen1,2, Diane L. Kamen3, Ted R Mikuls2, Frederick Wolfe4 and Kaleb Michaud2,4, 1Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 2Rheumatology, University of Nebraska Medical Center, Omaha, NE, 3Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 4National Data Bank for Rheumatic Diseases, Wichita, KS

    Background/Purpose: Despite more aggressive treatment strategies and new biologic DMARDs, the prevalence of osteoporosis (OP) leading to fracture in RA remains high. It is unknown…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology